Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Recombinant Vaccines Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The recombinant vaccines market size has seen rapid growth in recent years. It is forecast to increase from $15.79 billion in 2025 to $17.69 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. The expansion observed in the past can be ascribed to several factors, including the effectiveness of hepatitis B recombinant vaccines, long-standing global vaccination efforts, greater awareness regarding viral diseases, an increase in immunization funding, and regulatory backing for more secure vaccine platforms.
The recombinant vaccines market size is anticipated to undergo significant expansion in the coming years. Its valuation is projected to reach $28.07 billion by 2030, advancing at a compound annual growth rate (CAGR) of 12.2%. This expected growth throughout the forecast period stems from factors such as an escalating demand for precision vaccines, the broadening availability of vaccines for emerging diseases, an increase in adult booster programs, wider global immunization coverage, and a robust pipeline of recombinant candidates. Prominent trends for the forecast period encompass a rise in recombinant subunit vaccines, the expansion of vector-based vaccine platforms, more prevalent adult immunization programs, an increase in combination recombinant vaccines, and a heightened emphasis on long-lasting immunity.
Get A Free Sample Report With In-Depth Market Insights:
Recombinant Vaccines Market Growth Factors: What’s Supporting Expansion?
The rising occurrence of infectious diseases is projected to drive the expansion of the recombinant vaccines market in the future. An infectious disease refers to an ailment caused by germs (microorganisms) like bacteria, viruses, fungi, or parasites, capable of direct or indirect transmission between individuals. The spread of infectious diseases is escalating, attributed to substandard sanitation and hygiene practices, as insufficient availability of clean water, proper sanitation infrastructure, and efficient waste disposal facilitates the widespread distribution of detrimental microorganisms via tainted food, water, and direct contact, consequently elevating infection risks. Recombinant vaccines serve to prevent infectious diseases by employing genetically engineered material derived from pathogens to trigger an immune reaction without inducing sickness. For example, in July 2024, the Australian Institute of Health and Welfare, an Australia-based national agency, reported over 109,000 chlamydia and more than 40,000 gonorrhea notifications as the most frequently identified sexually transmitted infections in Australia during 2023. Additionally, over 6,400 cases of infectious syphilis were noted, underscoring the rising occurrence and persistent public health issues. Consequently, the rising prevalence of infectious diseases is fostering the expansion of the recombinant vaccines market.
Recombinant Vaccines Market Breakdown By Product Type And Application
The recombinant vaccines market covered in this report is segmented –
1) By Type: Subunit Vaccines; Vector-Based Vaccines
2) By Disease Indication: Human Papillomavirus (HPV); Herpes Zoster; Hepatitis B; Other Diseases
3) By Route Of Administration: Parenteral; Other Route Of Administrations
4) By End User: Pediatric; Adults
Subsegments:
1) By Subunit Vaccines: Protein Subunit Vaccines; Polysaccharide Subunit Vaccines; Conjugate Subunit Vaccines; Glycopeptide Subunit Vaccines; Recombinant Subunit Vaccines
2) By Vector-Based Vaccines: Viral Vector Vaccines; Non Viral Vector Vaccines; Replicating Vector Vaccines; Non Replicating Vector Vaccines; Bacterial Vector Vaccines
Recombinant Vaccines Market Industry Trends: What’s Reshaping Demand?
Major companies operating in the recombinant vaccines market are focusing on developing novel vaccines, such as the recombinant 9-valent HPV vaccine, to gain a competitive edge. The recombinant 9-valent HPV vaccine provides protection against nine types of human papillomavirus (HPV) and is created using recombinant DNA technology, meaning it is manufactured in a laboratory without live viruses, helping to prevent HPV-related diseases like cervical cancer and genital warts. For instance, in August 2023, Jiangsu Recbio Technology Co. Ltd., a biopharmaceutical company located in China, advanced REC603, its recombinant 9-valent HPV vaccine, through Phase III clinical follow-up with ongoing 24-month observations. The vaccine demonstrated strong immunogenicity, a favorable safety profile, scalable manufacturing potential, and long-term efficacy, supporting its potential for broad HPV prevention and commercialization.
Recombinant Vaccines Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the recombinant vaccines market are Johnson And Johnson, Merck And Co Inc., Pfizer Inc., Sanofi S. A., Novartis AG, AstraZeneca Plc, GlaxoSmithKline Plc, Mitsubishi Chemical Group Corporation, CSL Limited, Sinovac Biotech Ltd., Boehringer Ingelheim International GmbH, Zoetis Services Llc, Elanco Animal Health, BioNTech Se, Green Cross Corporation (Gc Biopharma), Bavarian Nordic A S, VBI Vaccines Inc., Vaxart Inc., Biological E Limited, Novavax Inc., Serum Institute Of India Private Limited, Vaxcyte Inc., Bharat Biotech International Limited, and Transgene S A.
View The Full Recombinant Vaccines Market Report:
Recombinant Vaccines Market Geographic Distribution And Regional Opportunities
North America was the largest region in the recombinant vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
